Studies using reduced intensity conditioning and allogeneic transplant for follicular lymphoma (based on reference1 ).
| Author (No. Pts.) . | Conditioning . | Stem Cell Source . | Median Follow-up (mo) . | PFS . | OS . | * TRM . | Comments . |
|---|---|---|---|---|---|---|---|
| * treatment-related mortality occurring in the first year after transplant | |||||||
| **Personal communication MB Maris, Fred Hutchinson Cancer Research Center | |||||||
| Abbreviations: PFS, progression-free survival; OS, overall survival; PB, peripheral blood; Flud, fludarabine; BEAM, BCNU/etoposide/cytarabine/melphalan; GVHD, graft-versus-host disease; TRM, treatment-related mortality | |||||||
| Seattle** (9) | Flud/TBI 200 | PB | >12 | 7 | 8 | 0 | |
| Khouri (20) | Flud/CY | PB | 21 | 80% | 80% | 20% | 64% cumulative incidence chronic GVHD |
| Faulkner (28) | BEAM Campath | PB | 16 | 69% | 74% | 16% | No extensive chronic GVHD |
| Robinson (28) | Flud/Alkylator (92%) BEAM Campath 8% | PB | NS | 29% | 39% | 39% | Higher than expected TRM and relapse |
| Author (No. Pts.) . | Conditioning . | Stem Cell Source . | Median Follow-up (mo) . | PFS . | OS . | * TRM . | Comments . |
|---|---|---|---|---|---|---|---|
| * treatment-related mortality occurring in the first year after transplant | |||||||
| **Personal communication MB Maris, Fred Hutchinson Cancer Research Center | |||||||
| Abbreviations: PFS, progression-free survival; OS, overall survival; PB, peripheral blood; Flud, fludarabine; BEAM, BCNU/etoposide/cytarabine/melphalan; GVHD, graft-versus-host disease; TRM, treatment-related mortality | |||||||
| Seattle** (9) | Flud/TBI 200 | PB | >12 | 7 | 8 | 0 | |
| Khouri (20) | Flud/CY | PB | 21 | 80% | 80% | 20% | 64% cumulative incidence chronic GVHD |
| Faulkner (28) | BEAM Campath | PB | 16 | 69% | 74% | 16% | No extensive chronic GVHD |
| Robinson (28) | Flud/Alkylator (92%) BEAM Campath 8% | PB | NS | 29% | 39% | 39% | Higher than expected TRM and relapse |